• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

多中心评价头孢他啶/他唑巴坦治疗碳青霉烯类耐药铜绿假单胞菌所致严重感染。

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.

机构信息

Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance.

Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA.

出版信息

Clin Infect Dis. 2017 Jul 1;65(1):158-161. doi: 10.1093/cid/cix014.

DOI:10.1093/cid/cix014
PMID:28329350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5850333/
Abstract

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

摘要

开展了一项多中心、回顾性研究，纳入了接受头孢洛扎/他唑巴坦治疗的耐碳青霉烯类铜绿假单胞菌感染患者。在 35 例患者中，肺炎是最常见的适应证，26 例（74%）治疗成功。在分离株头孢洛扎/他唑巴坦最低抑菌浓度≥8μg/mL 的所有情况下均观察到治疗失败。

相似文献

1
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.多中心评价头孢他啶/他唑巴坦治疗碳青霉烯类耐药铜绿假单胞菌所致严重感染。
Clin Infect Dis. 2017 Jul 1;65(1):158-161. doi: 10.1093/cid/cix014.
2
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.用头孢他啶/他唑巴坦成功治疗多重耐药铜绿假单胞菌突破性菌血症。
Infection. 2017 Feb;45(1):115-117. doi: 10.1007/s15010-016-0944-5. Epub 2016 Sep 26.
3
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.头孢洛扎他唑巴坦治疗多重耐药铜绿假单胞菌感染：临床疗效和耐药演变。
Clin Infect Dis. 2017 Jul 1;65(1):110-120. doi: 10.1093/cid/cix182.
4
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.多中心评估头孢他啶-阿维巴坦和头孢洛扎坦-他唑巴坦对血液、呼吸道和伤口来源的美罗培南不敏感铜绿假单胞菌的抑制活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
5
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).头孢洛扎/他唑巴坦对亚太地区（不包括中国、澳大利亚和新西兰）引起的医疗保健相关感染的耐药肠杆菌科和铜绿假单胞菌的活性：来自抗菌监测计划（2013-2015 年）的报告。
Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.
6
Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.成功治疗三例严重耐多药或广泛耐药铜绿假单胞菌感染的头孢他啶/他唑巴坦。
Future Microbiol. 2017 Nov;12:1323-1326. doi: 10.2217/fmb-2017-0018. Epub 2017 Oct 5.
7
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.头孢洛扎/他唑巴坦治疗多重耐药铜绿假单胞菌引起的呼吸道感染
Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28.
8
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.用头孢他洛锌-他唑巴坦进行挽救治疗耐多药铜绿假单胞菌感染
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02136-16. Print 2017 Mar.
9
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.头孢洛扎他唑巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂组合，对多种耐药性革兰氏阴性杆菌具有活性。
Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.
10
Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.头孢洛扎-他唑巴坦治疗血液恶性肿瘤和造血细胞移植受者中多重耐药铜绿假单胞菌感染。
Infection. 2018 Jun;46(3):431-434. doi: 10.1007/s15010-018-1125-5. Epub 2018 Feb 19.

引用本文的文献

1
Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.新型β-内酰胺/β-内酰胺酶抑制剂联合用药的临床疗效、安全性及药代动力学：一项系统评价
JAC Antimicrob Resist. 2025 Jun 19;7(3):dlaf096. doi: 10.1093/jacamr/dlaf096. eCollection 2025 Jun.
2
Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.重症患者难治性感染：综述与治疗建议
Antibiotics (Basel). 2025 Feb 11;14(2):178. doi: 10.3390/antibiotics14020178.
3
Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.头孢洛扎/他唑巴坦用于治疗医院环境中复杂性感染的法国真实世界研究
Open Forum Infect Dis. 2024 Feb 22;11(2):ofae037. doi: 10.1093/ofid/ofae037. eCollection 2024 Feb.
4
Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pneumonia for Patients Who Are Morbidly Obese.权衡利弊：新型β-内酰胺/β-内酰胺酶抑制剂在肥胖患者医院获得性肺炎和呼吸机相关性肺炎中的应用
Open Forum Infect Dis. 2023 Aug 28;10(9):ofad454. doi: 10.1093/ofid/ofad454. eCollection 2023 Sep.
5
Severe infections caused by difficult-to-treat Gram-negative bacteria.严重的感染由难以治疗的革兰氏阴性菌引起。
Curr Opin Crit Care. 2023 Oct 1;29(5):438-445. doi: 10.1097/MCC.0000000000001074. Epub 2023 Jul 31.
6
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA.美国得克萨斯州休斯顿市急性护理住院设施中接受头孢洛扎/他唑巴坦治疗的一组患者的临床特征、微生物学及治疗结果
JAC Antimicrob Resist. 2023 Jan 2;5(1):dlac131. doi: 10.1093/jacamr/dlac131. eCollection 2023 Feb.
7
Ceftolozane/Tazobactam Activity Against Drug-Resistant and Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016-2018).头孢洛扎/他唑巴坦对八个亚洲国家耐药且引起医疗保健相关感染的细菌的活性：一项抗菌监测计划（2016 - 2018年）的报告
Infect Drug Resist. 2022 Nov 22;15:6739-6753. doi: 10.2147/IDR.S387097. eCollection 2022.
8
Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR).头孢洛扎/他唑巴坦治疗菌血症：系统文献回顾（SLR）。
Ann Clin Microbiol Antimicrob. 2022 Oct 3;21(1):42. doi: 10.1186/s12941-022-00528-0.
9
Longitudinal Evolution of the Pseudomonas-Derived Cephalosporinase (PDC) Structure and Activity in a Cystic Fibrosis Patient Treated with β-Lactams.β-内酰胺类药物治疗囊性纤维化患者中假单胞菌来源头孢菌素酶（PDC）结构和活性的纵向演变。
mBio. 2022 Oct 26;13(5):e0166322. doi: 10.1128/mbio.01663-22. Epub 2022 Sep 8.
10
Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of and .Vitek 2和Etest与肉汤微量稀释法对头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦进行[具体细菌名称]药敏试验的比较评估
Antibiotics (Basel). 2022 Jun 27;11(7):865. doi: 10.3390/antibiotics11070865.

本文引用的文献

1
The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.高剂量黏菌素的有效性和安全性：前瞻性队列研究。
Clin Infect Dis. 2016 Dec 15;63(12):1605-1612. doi: 10.1093/cid/ciw684. Epub 2016 Oct 6.
2
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦：第二代β-内酰胺/β-内酰胺酶抑制剂组合
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
3
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
4
Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.黏菌素剂量对碳青霉烯耐药革兰阴性杆菌所致菌血症患者总体治愈率的影响
Antimicrob Agents Chemother. 2015 Nov 2;60(1):431-6. doi: 10.1128/AAC.01414-15. Print 2016 Jan.
5
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.头孢洛扎/他唑巴坦及其他胃肠外抗菌药物对美国医院分离的大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌的药敏谱
Clin Ther. 2015 Jul 1;37(7):1564-71. doi: 10.1016/j.clinthera.2015.05.501. Epub 2015 Jun 15.
6
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.头孢洛扎/他唑巴坦治疗多重耐药铜绿假单胞菌引起的呼吸道感染
Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28.
7
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).对 2011-2012 年美国医院分离的具有不同耐药模式的肠杆菌科和铜绿假单胞菌进行的头孢洛扎他唑巴坦的抗菌活性测试。
Antimicrob Agents Chemother. 2013 Dec;57(12):6305-10. doi: 10.1128/AAC.01802-13. Epub 2013 Oct 7.
8
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.2007 年至 2012 年加拿大 CANWARD 研究中，从加拿大医院患者分离的铜绿假单胞菌对头孢洛扎-他唑巴坦的体外活性。
Antimicrob Agents Chemother. 2013 Nov;57(11):5707-9. doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.
9
Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia.多药耐药革兰氏阴性菌血症患者中，黏菌素剂量与微生物学结局的关系。
Clin Infect Dis. 2013 Feb;56(3):398-404. doi: 10.1093/cid/cis909. Epub 2012 Oct 22.
10
Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients.黏菌素对治疗癌症患者中由多重耐药铜绿假单胞菌引起的感染有效。
Antimicrob Agents Chemother. 2007 Jun;51(6):1905-11. doi: 10.1128/AAC.01015-06. Epub 2007 Mar 26.